Professor Kluckow is a Senior Staff Specialist in Neonatology at Royal North Shore Hospital in Sydney and a Professor of Neonatology at the University of Sydney, Australia. With his Sydney based research group, he has led the development of neonatal haemodynamics and point of care ultrasound in the neonatal unit for the past 23 years, publishing over 95 peer reviewed articles.

His research has centered on the physiology and transitional circulation of infants born prematurely, the time frame of changes and the relationship of these changes to complications of prematurity. He has particular interests in the patent ductus arteriosus, management of hypertension and pulmonary hypertension, umbilical cord clamping time and ultrasound training and accreditation.

Professor Kluckow and his team develop and conduct new clinical studies in their quest to understand the problems with heart function in premature and sick infants receiving intensive care at Royal North Shore Hospital and in several collaborating hospitals around Australia.

All the studies that Professor Kluckow and his team work on are dependent on the access to a state-of-the-art ultrasound machine, donated by Heart Research Australia to Royal North Shore Hospital’s newborn intensive care unit.

To read more about the research Heart Research Australia is funding click here.

Latest Research

APTS (Australian Placental Transfusion Study)

Lead Researcher: Prof Martin Kluckow The first results of this trial were published in the New England Journal of Medicine showing that delayed cord clamping can reduce mortality in preterm infants and is safe to apply. The follow up of the trial is ongoing and Professor Kluckow and his team will continue to track these

Read More

The u-PDA Trial (Ultimate PDA Trial)

Lead Researcher: Prof Martin Kluckow This is a pilot randomized control trial (RCT) of active medical treatment vs supportive care alone of the patent ductus arteriosus (PDA) in babies born before 28 weeks of pregnancy. This placebo controlled clinical trial was the first time targeted early treatment of the patent ductus arteriosus (PDA) was utilised

Read More